TargetBeta
MYH7
myosin heavy chain 7 · also CMD1S, CMH1, MPD1 · Myosin heavy chains, class II
4 programs in company-led studies act on MYH7, from 3 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| mavacamtenrule | Bristol-Myers Squibb | phase 4 | 203 running | MYH6, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
| HRS-1893 | Jiangsu HengRui Medicine | phase 3 | 125 running | – | the company's pipeline |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 72 running | MYH6, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 161 running | MYH6, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
Conditions their studies are in
- Heart Failure, 3 programs
- Cardiomyopathy, Hypertrophic, 2 programs
- Anthrax, 1 program
- Cardiomyopathies, 1 program
- Cardiomyopathy, Dilated, 1 program
- Ventricular Dysfunction, Left, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027HRS-1893 · Jiangsu HengRui Medicine · phase 3 · NCT07269717
- Sep 2027danicamtiv · Bristol-Myers Squibb · phase 3 · NCT07210723
- Sep 2027omecamtiv mecarbil · Cytokinetics · phase 3 · NCT06736574
- Dec 13, 2027mavacamten · Bristol-Myers Squibb · phase 4 · NCT07004972
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.